TICKERNERD
Menu
STLNSTLNHealthcare · Medical Care Facilities

STLN Stock Forecast: Starling Oncology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$6.47
−1.15% on the day

The 5 Wall Street analysts covering Starling Oncology, Inc. hold a median 12-month price target of $9 — +39.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$658.9M
Ticker Nerd rank
62 / 100
Median analyst target
$9.00
Analysts covering
5
Total return, dividends reinvested
1W
+0.2%
From high
−2.9%
From low
+35.5%
$4.77
$6.66
Range since 29 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

STLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Starling Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Momentum
90
Accruals
84
Size
51
Quality
50
Revisions
47
Value
33
Issuance
28
Volatility
13

Growth (94): Sales and profits are climbing, and climbing faster than before.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STLN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $7.00Median $9.00High $11.00

The green dot is the last close — the median target sits +39.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026BTIGMaintainsBuy$8.00 → $9.00
9 July 2026BTIGMaintainsBuy—
6 July 2026Lake StreetInitiatesBuy$10
6 July 2026Lake StreetInitiatesBuy—
17 June 2026NeedhamMaintainsBuy—
8 June 2026BTIGMaintainsBuy—
13 Mar 2026B. Riley SecuritiesMaintainsBuy—
13 Mar 2026NeedhamReiteratesBuy—
9 Mar 2026BTIGReiteratesBuy—
9 Mar 2026NeedhamReiteratesBuy—
25 Nov 2025NeedhamInitiatesBuy—
21 Oct 2025BTIGReiteratesBuy—
16 July 2025B. Riley SecuritiesInitiatesBuy—
26 Feb 2024JefferiesAssumesBuy$2.50
16 June 2023GuggenheimMaintainsBuy—
20 Mar 2023GuggenheimMaintainsNeutral—
11 Nov 2022GuggenheimMaintainsBuy—
15 Aug 2022JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

STLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Starling Oncology, Inc. (STLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.0×

Cheaper than 94% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
−26.8×

Cheaper than 99% of US stocks

EV / EBITDA
−37.5×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
34.6%

Higher than 81% of US stocks

Earnings growth (YoY)
34.6%

Higher than 69% of US stocks

Gross margin
16.8%

Higher than 17% of US stocks

Operating margin
−2.9%

Higher than 29% of US stocks

Net margin
−6.2%

Higher than 23% of US stocks

Returns & dividend
Return on equity
320.0%

Higher than 99% of US stocks

Return on assets
−9.6%

Higher than 27% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

STLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
STLNStarling Oncology, Inc.$658.9M
62
GMRSGMR Solutions, Inc.$728.1M
1
SRTAStrata Critical Medical, Inc.$538.9M
46
CYHCommunity Health Systems, Inc.$416.9M
63
AUNAAuna SA$389.3M
52
USPHU.S. Physical Therapy, Inc.$1.2B
51
NUTXNutex Health, Inc.$1.3B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Starling Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STLN news & analysis

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

GlobeNewsWire · 17 Aug 2026positive

Starling Oncology announced the launch of Starling Oncology Nexus, a proprietary technology platform designed to address NCCN compliance and streamline the fragmented, administratively burdensome prior authorization process for oncology providers. The company described Nexus as built to optimize provider engagement and accelerate high-quality care at scale.

Why it matters — STLN watchers would care because the launch introduces a proprietary technology offering that could support the company's value-based community oncology operations by easing administrative burdens and encouraging guideline compliance.

Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Starling Oncology, Inc. (STLN). The item consists solely of the headline announcing the release of this transcript.

Why it matters — A STLN watcher would care because the earnings call transcript provides the company's full commentary on its latest quarterly results and outlook.

The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

The Oncology Institute, Inc. (STLN) reported a second-quarter loss of $0.08 per share, wider than the Zacks Consensus Estimate of a $0.07 loss but narrower than the $0.14 per-share loss from the same quarter a year ago. The company also surpassed revenue expectations for the quarter.

Why it matters — STLN watchers would care because the quarterly loss came in above the consensus estimate while revenue beat expectations, though the loss still exceeded analyst forecasts.

The Oncology Institute Rebrands as Starling Oncology

GlobeNewsWire · 3 Aug 2026neutral

The Oncology Institute, Inc., one of the largest value-based oncology groups in the United States, announced that it has rebranded to Starling Oncology, Inc.

Why it matters — A TOI watcher would care because the company's corporate identity is changing, which could affect how it is recognized and followed in the market.

The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call

GlobeNewsWire · 27 July 2026neutral

The Oncology Institute announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 5:00 p.m. the same day.

Why it matters — The earnings release and conference call will provide the company's latest financial results and operational update for the second quarter of 2026.

FAQ

Frequently asked questions about STLN stock

What is the STLN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Starling Oncology, Inc. have a median 12-month price target of $9, with estimates ranging from $7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STLN stock a buy right now?

Of the 5 analysts covering Starling Oncology, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Starling Oncology, Inc. 62 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STLN?

As at 22 Aug 2026, Starling Oncology, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will STLN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +39.2% from the last close, and Ticker Nerd's factor model ranks Starling Oncology, Inc. 62 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STLN stock forecast for 2030?

No analyst covering Starling Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $11 over the next 12 months.

What does Starling Oncology, Inc. do?

Starling Oncology, Inc. is a healthcare services company specializing in community-based oncology care in the United States.

What is the latest news on STLN?

The most recent item we track (GlobeNewsWire, 17 Aug 2026): "Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale". Starling Oncology announced the launch of Starling Oncology Nexus, a proprietary technology platform designed to address NCCN compliance and streamline the fragmented, administratively burdensome prior authorization process for oncology providers. The company described Nexus as built to optimize provider engagement and accelerate high-quality care at scale.

Company

About Starling Oncology, Inc.

Starling Oncology, Inc. is a healthcare services company specializing in community-based oncology care in the United States. The firm operates an integrated platform that delivers highly specialized, value-based cancer treatment, with services spanning physician consultations, in-house infusion, specialty pharmacy, radiation therapy, and outpatient blood product transfusions. Starling Oncology also provides access to comprehensive clinical trials and supportive offerings such as financial counseling, end-of-life counseling, patient education, and 24/7 assistance, targeting adult and senior cancer patients. Its business is organized across segments that include specialty pharmacy, patient services, and clinical trials and other, allowing it to coordinate both clinical care and associated therapies under one umbrella. Founded in 2007 and headquartered in Cerritos, California, Starling Oncology plays a significant role in the U.S. oncology market as one of the largest value-based oncology groups, operating more than 100 clinics and network locations across multiple states to deliver evidence-based, cost-conscious cancer care closer to where patients live.

CEO Dr. Daniel Virnich FACHE, M.B.A., M.D. · 641 employees · United States · https://starlingoncology.com